Portex® acapella® choice device distribution partnership into the Alternate Site and Home Care setting
MINNEAPOLIS–(BUSINESS WIRE)–Smiths Medical, a leading global medical device manufacturer, announced today it has partnered with Medline Industries for distribution of the Portex® acapella® choice vibratory PEP therapy device. This enhanced distribution partnership will be focused on the non-acute and home care channels.
“The distribution partnership with Medline provides improved access to our acapella® choice device for patients within the non-acute and home care settings,” said Nirav Sheth, Sr. Director of Global Marketing and General Manager at Smiths Medical. “This is an important channel within the full continuum of care, and we are very excited about what this opportunity brings to Smiths Medical, Medline, and the patients treated in non-acute settings.”
The Smiths Medical Portex® acapella® choice device is the market leading vibratory PEP device and is used to mobilize secretions and open airways. For more information, visit www.smiths-medical.com.
About Smiths Medical
A leading supplier of specialized medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. For more information, visit www.smiths-medical.com.
About Smiths Group
A global technology company that has been operating for 160 years, delivering products and services for the medical technology, security & defense, general industrial, energy and space & commercial aerospace markets worldwide. Smiths Group employs c. 22,000 colleagues in over 50 countries and is listed on the London Stock Exchange. For more information visit www.smiths.com.
Contacts
Keith Hoof
Phone: +1 (763) 383 3183
Email: keith.hoof@smiths-medical.com
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…
